HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Beth Hollister Selected Research

Beth Hollister Research Topics

Disease

6Neoplasms (Cancer)
08/2010 - 10/2002
1Residual Neoplasm
08/2010
1Retinoblastoma (Glioblastoma, Retinal)
10/2005
1Neoplasm Metastasis (Metastasis)
09/2004
1Carcinoma (Carcinomatosis)
10/2002
1Melanoma (Melanoma, Malignant)
10/2002

Drug/Important Bio-Agent (IBA)

3Pharmaceutical PreparationsIBA
03/2006 - 10/2002
2Phosphotransferases (Kinase)IBA
02/2008 - 09/2004
1Monoclonal AntibodiesIBA
08/2010
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
08/2010
1Blocking AntibodiesIBA
08/2010
1Complement System Proteins (Complement)IBA
08/2010
1JNJ 28871063IBA
02/2008
1Tyrosine (L-Tyrosine)FDA Link
02/2008
1PolymersIBA
03/2006
1IT-101IBA
03/2006
1Irinotecan (Camptosar)FDA LinkGeneric
03/2006
1CamptothecinIBA
03/2006
1Aurora KinasesIBA
10/2005
1JNJ-7706621IBA
10/2005
1CDC2 Protein Kinase (Protein p34cdc2)IBA
10/2005
1Cyclin-Dependent Kinases (cdk Proteins)IBA
10/2005
1Member 1 Subfamily B ATP Binding Cassette TransporterIBA
10/2005
1Doxorubicin (Adriamycin)FDA LinkGeneric
09/2004
1Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
09/2004
1Paclitaxel (Taxol)FDA LinkGeneric
09/2004
14- (4- (1- Amino- 1- methylethyl)phenyl)- 2- (4- (2- morpholin- 4- yl- ethyl)phenylamino)pyrimidine- 5- carbonitrileIBA
09/2004
1Angiogenesis InhibitorsIBA
09/2004
1SuspensionsIBA
10/2002
1rubitecanIBA
10/2002

Therapy/Procedure

2Therapeutics
08/2010 - 09/2004
1Duration of Therapy
08/2010
1Aftercare (After-Treatment)
09/2004